von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. - Wikidata - wikimedia - TriplyDB

von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.

von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.

http://www.wikidata.org/entity/Q46478024

about

A comprehensive overview of targeted therapy in metastatic renal cell carcinoma State of the science: an update on renal cell carcinoma Heritable Cancer Syndromes Related to the Hypoxia Pathway Molecular and immunologic markers of kidney cancer-potential applications in predictive, preventive and personalized medicine Molecular marker for predicting treatment response in advanced renal cell carcinoma: does the promise fulfill clinical need?Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis Predictive markers of efficacy for an angiopoietin-2 targeting therapeutic in xenograft models The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma.TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas.Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials.Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma.Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma.VHL, the story of a tumour suppressor gene.Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors.DNA methylation biomarkers predict progression-free and overall survival of metastatic renal cell cancer (mRCC) treated with antiangiogenic therapies.Future directions in renal cell carcinoma: 2011 and beyond New insights into the biology of renal cell carcinoma Tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanib.FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma.Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET).Differing von hippel lindau genotype in paired primary and metastatic tumors in patients with clear cell renal cell carcinoma.Emerging molecular classification in renal cell carcinoma: implications for drug development.Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance Stratification of clear cell renal cell carcinoma (ccRCC) genomes by gene-directed copy number alteration (CNA) analysis Analyses of Potential Predictive Markers and Response to Targeted Therapy in Patients with Advanced Clear-cell Renal Cell Carcinoma Vascularity of primary and metastatic renal cell carcinoma specimens.Prognostic Biomarkers for Response to Vascular Endothelial Growth Factor-Targeted Therapy for Renal Cell Carcinoma.Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer.Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer.Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney.Prognostic factors associated with the response to sunitinib in patients with metastatic renal cell carcinoma.VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy.Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma.

P2860

Q24606852-F2CFE0C0-CD62-4E39-A284-0B83DC2F977A Q24630685-A9C7BDB1-DB0F-4DEE-88A1-3BAC422929AA Q26751590-CBFA8555-C8B8-41B3-9BC8-2D9F687966D7 Q26779144-0F17D211-F083-451A-984D-7735B3350E92 Q26825512-7DA2D252-C243-457B-811E-218DFA6777B7 Q27003304-F94A8283-A670-4FF2-8D0B-C68917445D9D Q27302122-40DA1CF4-9F66-40B6-9504-AD72C3B74252 Q27852466-07CE976A-A54A-487F-ABE0-85F05BEFDF2E Q28067482-49C619EF-65FE-4575-8BB6-35BB8F171D53 Q30671049-727961FC-8187-4AD8-B20D-04EAF42EBBCD Q33688439-BF44A1C5-448A-49AF-A6D2-A845D8E8D08D Q33795896-8693C596-98F5-4B3D-8F87-0CEC6AFB5D4B Q34013801-8A9821EE-4A0E-4DDD-81C5-B23B318140E7 Q34105997-CDF8BF92-A5D5-46C9-9B2C-451A67DD7D39 Q34243444-51CC63E8-2EA3-4563-AD1E-C08B3E20E069 Q34365135-51EE26C1-153C-42E6-82CD-A95884637266 Q34455226-45F86F70-418C-4357-B5B3-59799257ECFB Q34572309-1D1A9E02-0D34-494D-928B-58E1C817F9C1 Q35122019-5385254A-5AFE-4A60-84A1-89D255FF604B Q35152107-0C33C5CB-79CD-481B-A99D-91F7CAF7A512 Q35180400-B6782D0E-2C0A-4B02-BC75-8E8BE76C8694 Q35534962-CAA2A0BA-0D50-463A-B649-71CEA542905B Q35583662-83BF798B-5927-4907-9AD4-76C1F4FF409A Q35909843-2EBEEC86-9FAD-4A88-B60D-31CE9DB67E02 Q35990536-949F03E8-6E93-45DD-9FAB-BCFF6A4C9755 Q36084718-98BF2821-F743-4EA2-9DDF-1D020F516DD9 Q36105139-D28B702C-126F-4942-BEFC-AEE39A646B54 Q36367103-BC0CAFD4-AC16-4831-AA48-6F63DDA94FC3 Q36477265-C3C83BC3-4EE8-48AC-B64B-616D2E1DC22F Q36578610-63636763-B148-4C00-BF98-9AB9CD2ACF6A Q36893510-154F1BF7-E9AE-4C38-94D2-980C4C6F60A0 Q37035437-D69DDEE7-6727-43DC-BD42-40DA30EA9EBB Q37151272-223F9038-2311-4271-BA42-23733C7DD5B0 Q37234734-0E55B712-1B2F-4658-8C4D-783B5338F604 Q37349768-B05B9BD8-2BCF-458A-86F3-28C219BB01F7 Q37364606-8785FD57-45BB-4A44-9ACA-355AD717BE3B Q37393004-800D380D-670F-49B6-B82B-7A3F47EC83CC Q37401553-68563852-018B-47C2-A894-1390379B76FC Q37437544-45DDC829-DA64-4F43-BC63-A86A3C915F98 Q37508022-5B535C8D-1CCA-497C-9D39-F6D5A7E5A421

P2860

von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.

http://www.wikidata.org/entity/Q46478024

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

von Hippel-Lindau gene status ...... ear cell renal cell carcinoma.

@en

von Hippel-Lindau gene status ...... ear cell renal cell carcinoma.

@nl

type

label

von Hippel-Lindau gene status ...... ear cell renal cell carcinoma.

@en

von Hippel-Lindau gene status ...... ear cell renal cell carcinoma.

@nl

prefLabel

von Hippel-Lindau gene status ...... ear cell renal cell carcinoma.

@en

von Hippel-Lindau gene status ...... ear cell renal cell carcinoma.

@nl

P1433

Q46478024-8CC201B8-43FB-4776-A49D-B08F80773860

P1476

Q46478024-9B55C2CB-0A13-4B55-8D43-9DD16B7ED7CF

P2093

Q46478024-00080AD4-4C68-4764-A1E3-743B00C939E5

Q46478024-12EDC4F8-E6B6-4846-9ACF-8A6233B4771B

Q46478024-36B0E676-F6B9-46F4-A99E-8C045D804EBC

Q46478024-38FE368F-E76B-4200-9E90-B1A2DED00D8E

Q46478024-633E9E66-9362-49EB-BFF7-A0FCD8323634

Q46478024-65F02BB3-5065-400F-84FA-3CE00CB947C5

Q46478024-80E186E4-062C-4EF0-B8B4-76EB538B0668

Q46478024-89B599A4-43DD-4684-B2A5-042BB59D639F

Q46478024-8B39EAFD-BD28-488E-9007-F7739146C1BB

Q46478024-8C4EE866-291A-4EF9-8F04-EBC3D6490B99

P304

Q46478024-8C57DF6D-6CC4-41C7-9DCD-2CF146DD130C

P31

Q46478024-C6D1816E-6238-4050-BFE6-326142707919

P356

Q46478024-8BA9439D-C8D4-4D5D-8A6E-D3548141682D

P407

Q46478024-E9DA4688-CB62-4034-8C8F-A5507E039A59

P433

Q46478024-2CCFE453-2C68-4FDD-9CFF-01B2723FB9BD

P478

Q46478024-F36B541D-C1F6-4323-AFD6-FA16E1AD19A8

P577

Q46478024-E3DDF157-00B6-40C0-A24E-E0A415E13FD3

P698

Q46478024-290EC6B8-E417-4E16-8387-E3DA2DB172D6

P356

J.JURO.2008.05.015

P1433

The Journal of Urology

P1476

von Hippel-Lindau gene status ...... ear cell renal cell carcinoma.

@en

P2093

Ali-Reza Golshayan

http://www.w3.org/2001/XMLSchema#string

Brian I Rini

http://www.w3.org/2001/XMLSchema#string

Eric J Small

http://www.w3.org/2001/XMLSchema#string

Erich Jaeger

http://www.w3.org/2001/XMLSchema#string

Frederic M Waldman

http://www.w3.org/2001/XMLSchema#string

Ish Prasad Bhalla

http://www.w3.org/2001/XMLSchema#string

Jeff Simko

http://www.w3.org/2001/XMLSchema#string

Laura Wood

http://www.w3.org/2001/XMLSchema#string

Linda Sercia

http://www.w3.org/2001/XMLSchema#string

Ming Zhou

http://www.w3.org/2001/XMLSchema#string

P304

860-5; discussion 865-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JURO.2008.05.015

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

180

http://www.w3.org/2001/XMLSchema#string

P577

2008-07-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18635227

http://www.w3.org/2001/XMLSchema#string